Share on Pinterest- Estrogen levels decrease during menopause, and this may increase the risk for Alzheimer’s disease.
- Experts are interested in understanding how the use of menopausal hormonal therapy affects Alzheimer’s disease risk.
- One retrospective study identified that estrogen-only menopausal hormonal therapy may help to protect against outcomes related to Alzheimer’s disease and dementia.
Menopause
is the complete end of experiencing menstrual periods, and it can increase the risk for certain health problems, such as stroke. A recent study published in Neurology, the medical journal of the American Academy of Neurology, notes that estrogen levels drop during menopause, and that this could lead to a higher risk for Alzheimer’s disease
This study found that estrogen-only menopausal hormonal therapy was associated with better Alzheimer’s disease and dementia outcomes
In the study, women who used estrogen-only menopausal hormonal therapy were less likely to show increased Alzheimer’s disease pathology, had lower chances of memory decline symptoms, and had lower chances of having a dementia diagnosis
However, much more research is required to fully determine the possible protective impact of estrogen-only menopausal hormonal therapy
How menopausal hormonal therapy affects dementia risk
The data on how menopausal hormonal therapy affects dementia is mixed, with many factors at play. The current research chose to focus exclusively on estrogen-only menopausal hormonal therapy and how this relates to aspects of Alzheimer’s disease and dementia
Researchers collected data from the National Alzheimer’s Coordinating Center (NACC) and the Alzheimer’s Disease Neuroimaging Initiative (ADNI)
From this first data set, they examined data from 258 participants who used estrogen-only menopausal hormone therapy and 2,701 participants who did not. From the second data set, there were 110 participants who used estrogen-only menopausal hormonal therapy and 1,948 participants who didn’t
This definition of estrogen-only menopausal hormonal therapy did not include topical use of estrogen. Researchers excluded participants who reported taking combinations of estrogen and progestin. A majority of participants were white, and the average age was between 71 and 72 years
For some participants, researchers were able to look at data from brain autopsies, allowing them to look at several components related to Alzheimer’s disease pathology, like amyloid deposits
Estrogen-only therapy linked to lower risk
Based on autopsy data, researchers found that participants using estrogen-only menopausal hormonal therapy had a lower chance of increased scores for Alzheimer’s disease pathology
Estrogen-only menopausal hormonal therapy was also linked to better outcomes in other brain areas, like lower chances of infarcts
, which are areas of tissue death because of a lack of blood supply
Researchers also found evidence that amyloid load was better for estrogen-only menopausal hormonal therapy users, which indicated better Alzheimer’s disease pathology compared to non-users
Among the NACC dataset, researchers found that estrogen-only users had a lower chance of having a clinical diagnosis of dementia and a lower chance of experiencing clinical decline
In the ADNI group, estrogen-only menopausal hormonal therapy was linked to better immediate memory and learning. A subgroup analysis of participants in the ADNI group who did not have dementia found that estrogen-only therapy was linked to better verbal memory
In addition to these outcomes, researchers also performed several exploratory analyses in subgroups, such as based on the type of estrogen-only menopausal hormonal therapy
What about those with genetic Alzheimer’s risk?
The researchers found that non-APOEe4 carriers who also used estrogen-only menopausal hormonal therapy had a lower chance of experiencing Alzheimer’s disease neuropathology
The researchers did not observe this result in APOE e4 carriers. The APOEe4 gene can increase the risk for Alzheimer’s disease. In both carriers and non-carriers, estrogen-only use was linked to less serious clinical diagnoses and better clinical dementia rating global scores
There were some differences when it came to the type of estrogen used. For example, conjugated estrogen users (people taking a blend of estrogen hormones) saw a lower chance of experiencing increased Alzheimer’s disease neuropathology, while the risk for those using estradiol was similar to that of non-estrogen users
Finally, starting estrogen-only menopausal hormonal therapy prior to age sixty was linked to a lower risk for Alzheimer’s disease neuropathology, but this link didn’t reach a level of statistical significance
Study author Jennifer Bruno, PhD, Instructor of Psychiatry and Behavioral Sciences at the Stanford University School of Medicine, explained the following regarding the study’s findings:
“We found that, on autopsy, women who had used estrogen-only hormone therapy had 35% lower odds of showing the hallmark brain changes of Alzheimer’s disease: amyloid plaques, tau tangles, and neuritic plaques, compared to women who had not used hormone therapy.”
“These autopsy findings were supported by blood and spinal fluid biomarkers collected while women were still living, which also pointed to lower levels of amyloid accumulation in the brain,” she continued
“In addition, estrogen-only hormone therapy users had lower odds of receiving a clinical dementia diagnosis and showed better performance on memory tests. Importantly, these associations held after we accounted for key risk factors including age, genetics, education, race, and hypertension,” she added
Study limitations
When it comes to limitations, it’s important to note that this study doesn’t establish any causality. It only shows associations. Second, there is a reliance on participant reporting, such as the self-report of estrogen-only menopausal hormonal therapy, sex, and age
A majority of the participants were white, limiting generalizability to other groups. There’s also limited generalizability because estrogen-only therapy is currently only appropriate for women who have had hysterectomies
The average age of participants also doesn’t relate to current practices of menopausal hormonal therapy, where doctors may prescribe estrogen-progesterone therapy to women in the period prior to menopause, perimenopause
Confounding is possible from multiple factors. Researchers note that the results could have been confounded “by improved pre-existing health status of the MHT [menopausal hormonal therapy] group.”
This research also only focused on estrogen-only therapy, so it cannot speak to the use of other hormones or hormone combinations. There was only autopsy data for a subgroup of participants, and some subgroup analyses were also limited, such as looking at the different types of estrogen therapy
Researchers were limited by the datasets they used, which included missing and sparse data. They were not able to confirm exactly when participants started hormone therapy. The authors note that the results cannot be generalized “to represent associations between life-time estrogen exposure and dementia outcomes” because they lacked data on how long estrogen-only menopausal hormonal therapy was used or on its use before the start of the study
They also lacked data on topical estrogen use in the NACC data set. The sample size in the ADNI data was also small, so the researchers note that the findings in this group are exploratory. Other secondary outcomes were also exploratory. Finally, funding came from several
Does estrogen have a protective effect against dementia?
This data suggests a possible protective effect of estrogen-only menopausal hormonal therapy, but there’s a major need for more research before major clinical changes can occur
Dung Trinh, MD, internist of MemorialCare Medical Group and Chief Medical Officer of Healthy Brain Clinic in Irvine, CA, who was not involved in the study, noted the following:
“The findings do not support prescribing menopausal hormone therapy specifically to prevent Alzheimer’s disease or dementia, since randomized trials have not established such a benefit. Instead, the study highlights the importance of taking a more individualized, life-course approach to women’s brain health.”
“Factors such as age at menopause, type and timing of hormone therapy, APOE status, vascular risk, and whether menopause was premature or surgical may eventually help clinicians better understand cognitive risk and personalize care, but more evidence is needed before these factors change routine Alzheimer’s prevention recommendations,” Trinh explained
Additionally, despite the possible protective effects of estrogen-only therapy, it’s not something that’s always appropriate
“Our findings are most directly relevant to women who have had a hysterectomy by age 60 (roughly 1 out of 3 women), since estrogen-only therapy is appropriate only for women without a uterus. For women with an intact uterus, combined estrogen-plus-progestin therapy is the standard approach,” Bruno noted
“For the subset of women who have had a hysterectomy, our results suggest that estrogen-only hormone therapy may have a protective association with Alzheimer’s-related brain changes. These findings do not change current clinical recommendations, but they do add an important new line of evidence: neuropathological data from autopsied brains,” she added
